{"filings":[{"id":249051,"accession_number":"0001831283-24-000004","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.05","3.01","7.01","8.01","9.01"],"status":"ready","headline":"LianBio to wind down operations, delist from Nasdaq, pay $4.80 special dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approves wind-down; workforce reduction of ~50% (over 50 employees) in Q1 2024.","Voluntary delisting from Nasdaq; last trading day expected March 18, 2024; OTC trading planned.","Special cash dividend of $4.80 per ordinary share/ADS (~$528M aggregate); record date Feb 27, payable ~March 11.","Estimated wind-down costs ~$17.2M, primarily severance; full dissolution expected first half 2027.","Company will pursue sale of remaining pipeline assets; any profits to be distributed to shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266588,"accession_number":"0001831283-23-000145","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"LianBio sells NBTXR3 rights in Asia to Janssen for $25M upfront plus potential $5M milestone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset Purchase Agreement with Janssen (Johnson & Johnson) executed Dec 22, 2023.","LianBio receives $25 million one-time payment at closing.","Eligible for $5 million milestone if annual net sales in PRC exceed $20 million.","Transition activities to be completed within six months post-closing.","Concurrent Novation Agreement with Nanobiotix consenting to the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266587,"accession_number":"0001831283-23-000141","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LianBio CFO Yi Larson resigns; Ehong Gu named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yi Larson resigned as CFO effective December 19, 2023, to pursue other opportunities.","Separation agreement provides severance of $2,430,124 paid in installments and lump sum.","Ehong Gu, VP Head of Global Finance, appointed interim CFO as principal financial officer.","Gu has held senior finance roles at CStone, BeiGene, and Celgene; no compensation terms set yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266586,"accession_number":"0001831283-23-000137","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LianBio CEO Yizhe Wang resigns; Adam Stone named interim CEO; Board to update on strategic review in Q1 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Yizhe Wang resigned effective Dec 16, 2023; receives severance of $1,525,000 plus accelerated vesting.","Board appoints Adam Stone (Perceptive Advisors CIO) as interim CEO; no compensation for service.","Board evaluating strategic alternatives; expects to communicate update in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266585,"accession_number":"0001831283-23-000133","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LianBio Board Unanimously Rejects $4.30/Share Unsolicited Bid from Concentra Biosciences","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously determined not to pursue unsolicited proposal from Concentra Biosciences.","Proposal was $4.30 per share cash plus contingent value right for 80% of net proceeds from license/disposition of programs.","Board concluded proposal undervalues the company and is not in the best interests of shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266584,"accession_number":"0001831283-23-000129","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LianBio confirms unsolicited $4.30/share buyout proposal from Concentra plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposal: $4.30 per share cash plus a contingent value right for 80% of net proceeds from licensing or disposition of LianBio's programs.","Concentra Biosciences (controlled by Tang Capital Partners) made the offer; Tang Capital currently holds ~8.6% of LianBio.","Proposal requires LianBio to have at least $515 million in cash and cash equivalents at closing, net of liabilities and costs.","Board is reviewing the unsolicited non-binding proposal in the best interests of shareholders; further announcement expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266583,"accession_number":"0001831283-23-000124","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LianBio Q3 net loss $24M, inks $350M BMS mavacamten deal, strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M in Q3 2023 vs $21.9M loss in Q3 2022; cash $252.2M as of Sep 30, 2023.","Entered agreement with BMS for mavacamten rights in China and other Asian markets for $350M total consideration.","Phase 3 TP-03 for Demodex blepharitis: mite eradication significant (p<0.001), collarette cure not significant (p=0.15); plans NDA filing.","Board initiated comprehensive strategic review in October 2023; update expected first half 2024."],"consensus_eps_estimate":-0.3399,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266582,"accession_number":"0001831283-23-000117","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","1.02","2.01","7.01","9.01"],"status":"ready","headline":"LianBio terminates mavacamten license for $350M; TP-03 Phase 3 shows mixed results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated mavacamten license with BMS/MyoKardia; receives $350M payment and released from $127.5M in milestones.","Phase 3 LIBRA trial met co-primary endpoint of mite eradication (p<0.001) but missed collarette cure (p=0.15).","Plans to discuss TP-03 results with NMPA and expects to file NDA for Demodex blepharitis in China.","Pro forma cash and equivalents rise to $444M (from $104M) after termination payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283824,"accession_number":"0001831283-23-000107","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LianBio Q2 2023 net loss narrows to $21.6M; cash $267.3M; mavacamten NDA under priority review in China","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.6M in Q2 2023 vs $42.4M in Q2 2022; R&D expenses fell to $9.5M from $28.6M.","Cash, equivalents and marketable securities $267.3M at June 30, 2023; runway into first half 2025.","Mavacamten NDA accepted with priority review by China NMPA; approved in Singapore and Macau.","Phase 3 EXPLORER-CN met primary endpoint; data to be presented at ESC Congress 2023.","TP-03 Phase 3 LIBRA fully enrolled; infigratinib Phase 2a in gastric cancer showed 25% ORR."],"consensus_eps_estimate":-0.2936,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303401,"accession_number":"0001831283-23-000092","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LianBio shareholders elect three Class II directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Susan Silbermann, Adam Stone, Wei Wei Chen elected as Class II directors with >95% votes in favor.","Ratification of KPMG LLP as independent auditor for FY 2023 received 105,454,707 votes for, 4,441 against.","Annual Meeting held June 21, 2023; 105,579,498 shares represented (98.5% of eligible)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303400,"accession_number":"0001831283-23-000079","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LianBio Q1 net loss $24M; mavacamten NDA accepted in China with priority review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M in Q1 2023 vs $27.7M in Q1 2022; cash $286.6M at March 31, 2023.","Phase 3 EXPLORER-CN trial of mavacamten met primary endpoint in Chinese oHCM patients.","China NMPA accepted mavacamten NDA with priority review; approved in Macau in May 2023.","Pascal Qian promoted to Chief Commercial Officer to lead mavacamten launch preparations.","Cash runway projected through end of 2024; key milestones for TP-03, infigratinib, BBP-398."],"consensus_eps_estimate":-0.2807,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303399,"accession_number":"0001831283-23-000073","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LianBio presents EXPLORER-CN topline data and mavacamten China opportunity at virtual event","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Virtual investor event held May 1, 2023 to discuss EXPLORER-CN topline data for mavacamten.","Slide presentation furnished as Exhibit 99.1 covers China market opportunity pending regulatory approval.","No specific numeric topline results (e.g., efficacy, safety) included in the filing text provided.","Event intended to provide overview of mavacamten's commercial potential in China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303398,"accession_number":"0001831283-23-000071","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"LianBio's mavacamten meets primary endpoint in Phase 3 EXPLORER-CN trial; NDA accepted with Priority Review in China","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EXPLORER-CN met primary endpoint: Valsalva LVOT gradient improvement from baseline to week 30 vs placebo (p<0.001).","All secondary endpoints met, including resting LVOT gradient, NYHA class improvement, KCCQ-CSS, and LV mass index.","Safety consistent with prior studies; no LVEF <50% requiring dose interruption.","NDA for mavacamten accepted with Priority Review by China NMPA for symptomatic oHCM.","LianBio to host analyst event May 1 to discuss topline data and China market opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303397,"accession_number":"0001831283-23-000067","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"China NMPA accepts with priority review LianBio's NDA for mavacamten in oHCM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA accepted NDA for mavacamten for symptomatic obstructive HCM in adults; priority review granted.","NDA based on global Phase 3 EXPLORER-HCM trial and LianBio's Phase 1 PK study in Chinese volunteers.","Blinded preliminary safety data from ongoing Phase 3 EXPLORER-CN trial supported early filing; topline results expected mid-2023.","CEO states this is a pivotal moment as LianBio prepares to become a commercial-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323029,"accession_number":"0001831283-23-000034","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LianBio reports FY2022 net loss of $110.3M; cash $302.4M with runway through end of 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.3M in Q4 2022 ($21.2M in Q4 2021); FY2022 loss $110.3M vs $196.3M in 2021.","Cash, cash equivalents and marketable securities $302.4M at Dec 31, 2022, down $100.8M from 2021.","Phase 3 EXPLORER-CN trial of mavacamten completed patient visits; topline data expected mid-2023.","Entered commercial agreement with Pfizer for sisunatovir; received $20M upfront, eligible for up to $135M milestones.","Phase 3 LIBRA trial of TP-03 for Demodex blepharitis ongoing; data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323028,"accession_number":"0001831283-23-000025","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Yi Larson gets new 3-year employment contract with $510K base salary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial term from Oct 1, 2022 to Sep 30, 2025, with auto-renewal for one-year periods.","Annual base salary $510,000; target discretionary bonus $255,000 per year.","Severance includes 12 months base salary plus repatriation expenses if terminated without cause or for good reason.","Within 12 months after a change in control, acceleration of unvested equity and relocation benefits added.","New contract replaces Sept 2021 agreement; includes perpetual confidentiality and 12-24 month non-compete/non-solicit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341107,"accession_number":"0001831283-22-000082","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Pfizer opts into LianBio's RSV drug sisunatovir rights in China & Singapore; $20M upfront, up to $135M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$20M upfront payment from previously restricted cash paid by Pfizer in 2020 under the existing strategic collaboration.","Up to $135M in potential development and commercial milestone payments plus tiered low single-digit percent of net sales.","Pfizer assumes all development/commercial costs in the region and releases LianBio from its royalty and milestone obligations to ReViral.","LianBio expects the transaction to extend cash runway through end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341106,"accession_number":"0001831283-22-000079","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LianBio President and Chief Strategy Officer Debra Yu resigns effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Debra Yu, President and CSO, resigns effective Jan 1, 2023 to pursue other business opportunities.","Yu entered a consulting agreement with LianBio from Jan 1 to June 30, 2023 to facilitate transition.","Separation agreement includes 12 months base salary, 14-month lump sum, and extended option exercisability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341105,"accession_number":"0001831283-22-000071","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LianBio Q3 net loss $21.9M; cash $331.8M; mavacamten Phase 3 data expected mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.9M for Q3 2022 vs $13.1M YoY; R&D expenses $8.3M, G&A $16.3M.","Cash, cash equivalents, securities $331.8M at Sep 30, 2022, down from $403.2M Dec 31, 2021; runway into 2H 2024.","Mavacamten Phase 3 EXPLORER-CN data expected mid-2023; NDA submitted in Hong Kong; included in Chinese HCM guidelines.","TP-03 Phase 3 LIBRA trial for Demodex blepharitis initiated in China; data expected Q4 2023; US NDA accepted, PDUFA Aug 25, 2023.","Phase 3 NANORAY-312 (NBTXR3) for head & neck cancer initiated in Asia; Phase 1 BBP-398 dosing begun."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341104,"accession_number":"0001831283-22-000064","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LianBio halts infigratinib CCA program after Helsinn exits US market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Helsinn Healthcare SA permanently discontinues Truseltiq (infigratinib) in US; plans to withdraw NDA for business reasons.","BridgeBio closing global Phase 3 PROOF-301 trial of infigratinib in first-line cholangiocarcinoma (CCA).","LianBio terminating all CCA development in China; no longer pursuing infigratinib for CCA in licensed territories.","LianBio will continue supporting existing patients under the Hainan Named Patient Program.","LianBio expects to continue Phase 2a trial of infigratinib in gastric cancer and other FGFR-altered solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358215,"accession_number":"0001831283-22-000059","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LianBio Q2 net loss $42.4M; cash $349.4M; mavacamten China Phase 3 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.4M in Q2 2022 vs. $100.4M loss in Q2 2021; R&D expenses fell to $28.6M.","Cash balance $349.4M at June 30, 2022; runway projected into second half of 2024.","Completed enrollment in China Phase 3 EXPLORER-CN trial of mavacamten; topline data mid-2023.","Submitted NDAs: mavacamten in Singapore (oHCM) and infigratinib in Hong Kong (cholangiocarcinoma).","Three additional registration-enabling programs (TP-03, NBTXR3, BBP-398) to begin in China by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376947,"accession_number":"0001831283-22-000044","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LianBio shareholders elect two Class I directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tassos Gianakakos received 89,412,158 votes for; 502,057 against; 3,399,403 abstained.","Neil Kumar received 83,460,880 votes for; 6,453,135 against; 3,399,603 abstained.","KPMG LLP ratified as independent auditor for FY2022: 89,906,342 for, 11,223 against, 3,396,053 abstained.","No broker non-votes on any proposal; quorum of 93,313,618 shares out of 107,275,458 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376946,"accession_number":"0001831283-22-000037","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LianBio Q1 net loss narrows to $27.7M; cash $389.1M; mavacamten FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.7M vs $61.6M in Q1 2021; R&D expenses fell to $12.3M from $53.4M.","Cash balance $389.1M as of March 31, 2022; runway projected through mid-2024.","Partner BMS received U.S. FDA approval for mavacamten in obstructive HCM in April 2022.","Partner Tarsus reported positive Phase 3 Saturn-2 data for TP-03 in Demodex blepharitis; NDA planned H2 2022.","Pfizer agreed to acquire development partner ReViral (sisunatovir); LianBio expects to start three Phase 3 trials in China by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376945,"accession_number":"0001831283-22-000021","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LianBio appoints Wei Wei Chen as independent director and Audit Committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wei Wei Chen appointed to LianBio Board as Class II director effective April 6, 2022; term ends at 2023 annual shareholder meeting.","Chen also appointed to the Audit Committee of the Board.","Chen brings 17+ years CFO experience, most recently at Starbucks China; previously CFO at Yum! Brands China and Sanofi Asia.","No arrangement or understanding with any other person led to selection; no related-party transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395296,"accession_number":"0001831283-22-000012","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LianBio reports Q4 net loss $21.2M; cash $403.2M; mavacamten Phase 3 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.2M in Q4 2021 vs $12.7M Q4 2020; full-year loss $196.3M vs $139.6M.","Cash, equivalents, marketable securities $403.2M at Dec 31, 2021; runway through 2023.","Phase 3 EXPLORER-CN trial of mavacamten initiated in Chinese oHCM patients; Breakthrough Therapy designation granted.","Infigratinib approved under named patient program for cholangiocarcinoma in Hainan pilot zone.","Three programs (TP-03, NBTXR3, infigratinib) expected to enter Phase 3 in China by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395295,"accession_number":"0001831283-22-000005","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LianBio posts corporate presentation with pipeline and strategy updates (details not fully disclosed)","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation posted to company website on March 2, 2022.","Presentation covers pipeline progress, clinical programs, and strategic priorities as of March 2022.","No specific financial results, guidance, or material developments disclosed in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414010,"accession_number":"0001193125-21-352750","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LianBio Q3 net loss narrows to $13.1M; completed $334.5M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.1M ($0.63 per share) narrowed from $120.2M ($11.71) in Q3 2020.","R&D expenses fell to $4.7M from $116.9M; G&A increased to $8.9M from $2.1M.","Completed IPO raising $334.5M gross ($311.1M net); cash position sufficient through 2023.","Initiated PK study of mavacamten and Phase 2a trial of infigratinib in China.","Appointed Jesse Wu and Susan Silbermann to board; new chief scientific advisor and China GM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414009,"accession_number":"0001193125-21-326065","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"LianBio subsidiary signs lease for Shanghai HQ; total base rent ~$4.9M through March 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 2,313.46 sq m office space at Corporate Avenue, Shanghai; initial term Nov 16, 2021 to Mar 31, 2025.","Total base rent plus management fees ~$4.9M (excl. VAT) over initial term, payable monthly; plus additional fees.","Lessee has one-time renewal right for three years at then-prevailing market terms.","Premises will be used as LianBio's Shanghai corporate headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414008,"accession_number":"0001193125-21-318383","cik":1831283,"company_name":"LianBio","ticker":"LIANY","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"LianBio files amended charter authorizing 2.9B ordinary shares upon IPO closing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized 2,923,900,005 ordinary shares via amended memorandum and articles of association.","Amendment effective upon IPO closing on November 3, 2021.","Amended charter substantially in form previously filed in S-1 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15010310.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}